SCHEMBL6554792

SCHEMBL6554792

COc1cc(CCNC(=O)C(NS(C)(=O)=O)C(C)C)ccc1O[C@@H](C)COc1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 2/20 0.47
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
LMNA P02545 4/20 0.46
CNR1 P21554 1/20 0.46
CTSD P07339 1/20 0.44
POLB P06746 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6554789 1.00 KMT2A (0.49) KMT2AMEN1GAAALDH1A1SMN1; SMN2
SCHEMBL6556864 0.92 KMT2A (0.48) KMT2AMEN1GAAALDH1A1SMN1; SMN2
SCHEMBL6556859 0.92 KMT2A (0.48) KMT2AMEN1GAAALDH1A1SMN1; SMN2
SCHEMBL6556870 0.92 KMT2A (0.48) KMT2AMEN1GAAALDH1A1SMN1; SMN2
SCHEMBL6554738 0.89 KMT2A (0.51) KMT2AMEN1GAAALDH1A1SMN1; SMN2
SCHEMBL13350377 0.85 KMT2A (0.52) KMT2AMEN1GAAALDH1A1SMN1; SMN2
SCHEMBL6553795 0.84 KMT2A (0.51) KMT2AMEN1GAAALDH1A1SMN1; SMN2
SCHEMBL483297 0.82 KMT2A (0.48) KMT2AMEN1GAAALDH1A1SMN1; SMN2
SCHEMBL82268 0.82 KMT2A (0.48) KMT2AMEN1GAAALDH1A1SMN1; SMN2
SCHEMBL29419083 0.82 KMT2A (0.48) KMT2AMEN1GAAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1135368-B1 ALPHA-SULFIN- AND ALPHA-SULFON-AMINO ACID AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2004-02-25 EP disclosed
US-6538016-B2 For controlling and preventing an infestation of crop plants by phytopathogenic microorganisms, preferably fungi SYNGENTA PARTICIPATIONS AG (CH) 2003-03-25 US disclosed
US-20020082452-A1 alpha-sulfin-and alpha-sulfonamino acid amides SYNGENTA PARTICIPATIONS AG (CH) 2002-06-27 US disclosed
EP-1135368-A2 ALPHA-SULFIN- AND ALPHA-SULFON-AMINO ACID AMIDES Syngenta Participations AG (CH) 2001-09-26 EP disclosed
WO-2000032568-A2 $G(A)-SULFIN- AND $G(A)-SULFONAMINO ACID AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2000-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082452-A1 alpha-sulfin-and alpha-sulfonamino acid amides SULT1A1, CBR1, SULT2A1 KMT2A 2647/4885MEN1 3649/4885GAA 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.